Jim Simons Abb Vie Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Abb Vie Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,128,994 shares of ABBV stock, worth $188 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares

1,128,994

Previous 1,996,711 43.46%

Holding current value

$188 Million

Previous $309 Million 33.56%

% of portfolio

0.32%

Previous 0.48%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$159.82 - $182.1 $139 Million - $158 Million	-867,717 Reduced 43.46%	1,128,994 $206 Million
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $87.9 Million - $99 Million	638,612 Added 47.02%	1,996,711 $309 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $9.48 Million - $11 Million	70,991 Added 5.52%	1,358,099 $202 Million
Q2 2023 Aug 11, 2023	BUY	$132.51 - $164.9 $128 Million - $159 Million	964,212 Added 298.61%	1,287,108 $173 Million
Q1 2023 May 12, 2023	SELL	$144.61 - $166.54 $2.3 Million - $2.65 Million	-15,900 Reduced 4.69%	322,896 $51.5 Million

Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $3.68 Million - $4.41 Million	-26,606 Reduced 7.28%	338,796 $54.8 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $132 Million - $152 Million	-985,578 Reduced 72.95%	365,402 $49 Million
Q2 2022 Aug 12, 2022	BUY	$137.62 - $174.96 $58.9 Million - $74.8 Million	427,677 Added 46.32%	1,350,980 $207 Million
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $149 Million - $185 Million	-1,130,274 Reduced 55.04%	923,303 $150 Million
Q4 2021 Feb 11, 2022	SELL	$107.43 - $135.93 $1.86 Million - $2.35 Million	-17,317 Reduced 0.84%	2,053,577 $278 Million
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $143 Million - $162 Million	1,340,970 Added 183.71%	2,070,894 $223 Million
Q2 2021 Aug 13, 2021	SELL	$105.21 - $117.21 $12.3 Million - $13.7 Million	-117,113 Reduced 13.83%	729,924 $82.2 Million
Q1 2021 May 13, 2021	SELL	$102.3 - $112.62 $534 Million - $587 Million	-5,215,538 Reduced 86.03%	847,037 $91.7 Million
Q4 2020 Feb 10, 2021	SELL	$80.49 - $108.67 $596 Million - $805 Million	-7,408,228 Reduced 54.99%	6,062,575 $650 Million
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $477 Million - $560 Million	-5,551,066 Reduced 29.18%	13,470,803 $1.18 Billion
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $401 Million - $537 Million	5,466,020 Added 40.32%	19,021,869 $1.87 Billion
Q1 2020 May 14, 2020	BUY	$64.5 - $97.79 $113 Million - $172 Million	1,759,105 Added 14.91%	13,555,849 $1.03 Billion
Q4 2019 Feb 13, 2020	BUY	$72.13 - $90.25 $324 Million - $405 Million	4,490,046 Added 61.45%	11,796,744 $1.04 Billion
Q3 2019 Nov 13, 2019	BUY	$62.98 - $75.72 $174 Million - $210 Million	2,768,156 Added 60.99%	7,306,698 $553 Million
Q2 2019 Aug 12, 2019	BUY	$65.7 - $83.98 $136 Million - $173 Million	2,064,486 Added 83.45%	4,538,542 $330 Million
Q1 2019 May 14, 2019	BUY	$77.14 - $90.79 $183 Million - $216 Million	2,374,556 Added 2386.49%	2,474,056 $199 Million
Q4 2018 Feb 13, 2019	BUY	$77.85 - $96.01 $7.75 Million - $9.55 Million	99,500 New	99,500 $9.17 Million

Others Institutions Holding ABBV

# of Institutions

3,641

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $294B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account